A 48-year-old woman with type 2 diabetes is on metformin 1500 mg/day and gliclazide 80 mg/day. Her HbA1c is 8.1% and fasting glucose is 148 mg/dL. She reports 2–3 episodes of symptomatic hypoglycemia per month, occurring mostly in the early morning. Her BMI is 26 kg/m² and eGFR is 62 mL/min/1.73m². What is the most appropriate modification to her current regimen?

Explanation

## Clinical Problem Identification This patient presents a paradox: inadequate glycemic control (HbA1c 8.1%) **coexisting with recurrent hypoglycemia** (2–3 episodes/month). This pattern is pathognomonic for **brittle diabetes** or **glucose variability** — typically seen with sulfonylurea overuse. ## Pathophysiology of Sulfonylurea-Induced Hypoglycemia **Key Point:** Sulfonylureas cause insulin secretion independent of blood glucose levels, creating a mismatch between endogenous insulin and actual glucose availability. **High-Yield:** The combination of: - Fasting hyperglycemia (148 mg/dL) - Recurrent hypoglycemia (early morning) - High HbA1c (8.1%) ...indicates **glucose swings** — the patient overshoots insulin effect at night (causing hypoglycemia) and rebounds during fasting (causing hyperglycemia). This is NOT solved by increasing the sulfonylurea dose. ## Why GLP-1 Agonist is the Solution | Feature | Sulfonylurea | GLP-1 Agonist | | --- | --- | --- | | Hypoglycemia risk | High (glucose-independent) | Very low (glucose-dependent) | | Weight effect | Gain (+2–3 kg) | Loss (−2–4 kg) | | HbA1c reduction | 1–2% | 1–1.5% | | Cardiovascular benefit | Neutral/harmful | Proven CV protection | | Renal safety | Safe | Renal protection (GFR >30) | | Mechanism | Stimulates insulin release | Enhances GLP-1 signaling | **Clinical Pearl:** GLP-1 agonists (exenatide, dulaglutide, semaglutide) are **glucose-dependent** — they only stimulate insulin when blood glucose is elevated, making hypoglycemia rare. They also improve β-cell function and promote weight loss. **Mnemonic: "GLP-1 = Glucose-dependent, Low hypoglycemia, Protects organs"** ## Why Exenatide Specifically? 1. **Hypoglycemia prevention:** Glucose-dependent mechanism eliminates the brittle pattern 2. **Weight loss:** Beneficial for BMI 26 (modest overweight) 3. **Cardiovascular protection:** Proven CV benefit in trials 4. **Renal safety:** Safe at eGFR 62 mL/min/1.73m² (caution below 30) 5. **Efficacy:** HbA1c reduction of 1–1.5% when added to metformin ## Rationale for Discontinuing Gliclazide Replacing (not adding) gliclazide with exenatide: - Eliminates the source of hypoglycemia - Maintains dual therapy (metformin + GLP-1) - Reduces treatment complexity - Improves safety profile [cite:KD Tripathi 8e Ch 29; Harrison 21e Ch 417] ## Why Other Options Fail **Increasing gliclazide:** This is the cardinal error. The problem is NOT insufficient insulin — it is **erratic insulin secretion**. More sulfonylurea will worsen glucose swings and hypoglycemia. **Adding pioglitazone:** While insulin-sensitizing, it does not address the root cause (sulfonylurea-induced hypoglycemia) and adds weight gain risk in an already overweight patient. **Switching to insulin:** Premature and shifts burden to exogenous insulin management. Oral agents remain viable; insulin is reserved for failure of multiple oral agents.